Regulatory Reform Author: Kathryn S. Brown
Listening to the radio on his way to work each morning in Washington D.C., Stephen Bent, chairman of the biotechnology and pharmaceutical group at the law firm of Foley and Lardner, hears the same thing: advertisements calling for drastic reform of the Food and Drug Administration (FDA).
"Some of the commercials are by a Republican think tank," notes Bent, formerly a research scientist in neurophysiology at Yale University. "Some are by various interest groups. And some, I just don't know who they're by."
But Bent says he does know one thing: "Phar- maceutical corporations are on a bandwagon whose time has come." In an era of pro-streamlining, anti-regulatory, pro-corporate sentiment, Bent predicts, pharmaceutical and biotech companies stand to win or gain ground in many regulatory battles with various government agencies.
The new year offers plenty of issues. As 1996 begins, companies are poised to ...
